Prothena (NASDAQ:PRTA) Shares Gap Up Following Analyst Upgrade
Prothena (NASDAQ:PRTA) Shares Gap Up Following Analyst Upgrade
Shares of Prothena Co. plc (NASDAQ:PRTA – Get Rating) gapped up prior to trading on Wednesday after Royal Bank of Canada raised their price target on the stock from $45.00 to $52.00. The stock had previously closed at $30.93, but opened at $49.45. Prothena shares last traded at $56.83, with a volume of 67,230 shares.
周三，在加拿大皇家银行将普罗塞纳股份有限公司(纳斯达克：PRTA-GET评级)的目标价从45美元上调至52美元后，该公司股价在开盘前大幅上涨。该股此前收盘报30.93美元，开盘报49.45美元。Prothena的股票最后交易价格为56.83美元，成交量为67,230股。
A number of other research firms have also recently commented on PRTA. Bank of America raised shares of Prothena from a "neutral" rating to a "buy" rating and increased their target price for the stock from $45.00 to $65.00 in a report on Wednesday. JMP Securities raised their price objective on shares of Prothena from $50.00 to $81.00 in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $67.75.
其他一些研究公司最近也对PRTA发表了评论。美国银行周三在一份报告中将普罗塞纳的股票评级从中性上调至买入，并将该股目标价从45.00美元上调至65.00美元。JMP证券在周三的一份报告中将Prothena的股票目标价从50.00美元上调至81.00美元。一名股票研究分析师对该股的评级为持有，三名分析师对该公司股票的评级为买入。根据MarketBeat的数据，该股的普遍评级为“适度买入”，平均目标价为67.75美元。
Insider Buying and Selling
内幕买卖
In related news, insider Hideki Garren sold 8,000 shares of the stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $30.00, for a total value of $240,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Hideki Garren sold 8,000 shares of the stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $30.00, for a total value of $240,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Tran Nguyen sold 42,120 shares of the firm's stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $32.49, for a total value of $1,368,478.80. Following the transaction, the chief financial officer now owns 3,200 shares in the company, valued at $103,968. The disclosure for this sale can be found here. Insiders have sold a total of 148,498 shares of company stock worth $4,750,606 in the last ninety days. Corporate insiders own 31.20% of the company's stock.
在相关新闻中，内部人士Hideki Garren在7月6日星期三的一笔交易中出售了8000股该股。这只股票的平均售价为30.00美元，总价值为240,000.00美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可以通过这个环节。在相关新闻中，内部人士Hideki Garren在7月6日星期三的一笔交易中出售了8000股该股。这只股票的平均售价为30.00美元，总价值为240,000.00美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可以通过这个环节。此外，CFO Tran Nguyen在7月20日星期三的一笔交易中出售了42,120股该公司的股票。这些股票的平均价格为32.49美元，总价值为1,368,478.80美元。交易完成后，这位首席财务官现在拥有该公司3200股股票，价值103,968美元。关于这次销售的披露可以找到这里。在过去的90天里，内部人士总共出售了148,498股公司股票，价值4,750,606美元。公司内部人士持有该公司31.20%的股份。
Hedge Funds Weigh In On Prothena
对冲基金看好普罗塞纳
Prothena Stock Up 87.5 %
普罗塞纳股票上涨87.5%
The company has a 50-day simple moving average of $30.70 and a two-hundred day simple moving average of $30.63. The stock has a market cap of $2.72 billion, a P/E ratio of -241.67 and a beta of 1.33.
该公司的50日简单移动均线切入位在30.70美元，200日简单移动均线切入位在30.63美元。该股市值为27.2亿美元，市盈率为-241.67，贝塔系数为1.33%。
Prothena (NASDAQ:PRTA – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.37). Prothena had a negative net margin of 1.03% and a negative return on equity of 0.33%. The company had revenue of $1.31 million during the quarter, compared to the consensus estimate of $20.12 million. As a group, sell-side analysts forecast that Prothena Co. plc will post -2.57 earnings per share for the current fiscal year.
普罗塞纳(纳斯达克：PRTA-GET Rating)上一次公布季度收益数据是在8月8日星期一。这家生物技术公司公布了本季度每股收益(0.88美元)，低于普遍预期的(0.51美元)和(0.37美元)。普罗塞纳的净利润率为负1.03%，股本回报率为负0.33%。该公司本季度营收为131万美元，而市场普遍预期为2012万美元。卖方分析师预计，普罗塞纳公司本财年每股收益将达到2.57欧元。
About Prothena
关于普罗塞纳
(Get Rating)
(获取评级)
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Prothena Corporation plc是一家晚期临床公司，专注于在美国发现和开发威胁生命的疾病的新疗法。该公司参与开发了治疗AL淀粉样变性的研究性人源化抗体BirTamimab、治疗帕金森氏病的人源化单抗Prasinezumab、治疗转甲状腺素淀粉样变性的第一阶段临床试验的PRX004以及治疗阿尔茨海默病的第一阶段临床试验的PRX005。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Prothena (PRTA)
- Can HCA Healthcare Weather the Normalization?
- Can United Natural Foods Fight Both Inflation and the Fed?
- Mullen Automotive Is Ready To Get In Gear
- Cracker Barrel: A Tasty Treat Or Bad Apple?
- Defensive Stocks For A Volatile Market
- 免费获取StockNews.com关于普罗塞纳的研究报告(PRTA)
- HCA医疗能否经受住正常化的考验？
- 联合天然食品能同时对抗通胀和美联储吗？
- 马伦汽车已做好准备投入使用
- 饼干桶：可口的款待还是坏苹果？
- 防御性股票应对动荡的市场
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.
接受《普罗塞纳日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Prothena和相关公司的最新新闻和分析师评级的每日简要摘要。